Back to top
more

Amicus Therapeutics (FOLD)

(Real Time Quote from BATS)

$11.00 USD

11.00
928,895

+0.09 (0.83%)

Updated Sep 19, 2024 02:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Amicus (FOLD) Banks on Galafold, High Dependence a Concern

Amicus' (FOLD) lead drug, Galafold, is witnessing solid sales uptake so far. The approval for Pombiliti + Opfolda also aids sales. However, overdependence on Galafold for revenues remains a concern.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Amicus (FOLD) Up as Q2 Earnings & Sales Top, '24 View Updated

Amicus (FOLD) rises 13% as it reports second-quarter 2024 results, wherein both earnings and sales beat the Zacks Consensus Estimate. The company updates its financial guidance for 2024.

Amicus Therapeutics (FOLD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Amicus Therapeutics (FOLD) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Amicus Therapeutics (FOLD) Q2 Earnings and Revenues Top Estimates

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 100% and 4.90%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates

Certara (CERT) delivered earnings and revenue surprises of -36.36% and 1.78%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Do Options Traders Know Something About Amicus (FOLD) Stock We Don't?

Investors need to pay close attention to Amicus (FOLD) stock based on the movements in the options market lately.

Do Options Traders Know Something About Amicus (FOLD) Stock We Don't?

Investors need to pay close attention to Amicus (FOLD) stock based on the movements in the options market lately.

Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated

Amicus (FOLD) reports first-quarter 2024 results, wherein earnings beat the Zacks Consensus Estimate but sales miss the same. The company updates its financial guidance for 2024.

Amicus Therapeutics (FOLD) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for Amicus Therapeutics (FOLD) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Amicus Therapeutics (FOLD) Reports Q1 Loss, Lags Revenue Estimates

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 66.67% and 1.09%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates

Clene (CLNN) delivered earnings and revenue surprises of 0% and 54.38%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Amicus Therapeutics (FOLD) Report Negative Q1 Earnings? What You Should Know

Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Amicus Therapeutics (FOLD) Down 8.1% Since Last Earnings Report?

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Amicus' (FOLD) Q4 Earnings Beat, Revenues Meet Estimates

Amicus' (FOLD) fourth-quarter earnings beat estimates while revenues meet the same. Stock down.

Amicus Therapeutics (FOLD) Reports Q4 Loss, Lags Revenue Estimates

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -83.33% and 0.02%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Amicus (FOLD) Stock Rises More Than 25% in 3 Months: Here's Why

Sales of Amicus' (FOLD) lead drug, Galafold, are rising consistently. Also, the recent approval of the Pompe disease drug combination, Pombiliti + Opfolda, is a positive.

Amicus (FOLD) Issues Preliminary Revenue Results for FY23

Amicus (FOLD) posts preliminary results for full-year 2023. The company also provides a strategic outlook for 2024.

Amicus (FOLD) Banks on Galafold, Overdependence a Concern

Amicus' (FOLD) lead drug, Galafold, is witnessing solid uptake since its launch. The drug holds blockbuster potential. However, overdependence on Galafold for revenues remains a concern.

Why Is Amicus Therapeutics (FOLD) Up 15% Since Last Earnings Report?

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Amicus' (FOLD) Q3 Loss Narrows, Galafold Sales View Updated

Amicus (FOLD) incurs a narrower-than-expected loss in the third quarter. However, revenues beat estimates. The company tightens Galafold revenue guidance for 2023.

Synlogic, Inc. (SYBX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Synlogic, Inc. (SYBX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amicus Therapeutics (FOLD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.